文献速递临床试验与 GCP基础与转化研究

肿瘤浸润淋巴细胞治疗抗PD-1耐药转移性肺癌的1期试验

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
PubMed 文献 · Nat Med · 2021-08-12

这项单臂开放标签1期试验在20例纳武利尤单抗单药治疗后进展的晚期非小细胞肺癌患者中评估TILs联合纳武利尤单抗的安全性与活性。安全性终点按预设标准达成,13例可评估患者中3例确认缓解、11例肿瘤负荷下降,中位最佳变化35%。探索性分析发现治疗后出现识别多种癌症突变的T细胞且在缓解者中富集,新抗原反应性T细胞克隆在外周血中增加并持续存在。

要点

  • TILs联合纳武利尤单抗在经纳武利尤单抗治疗进展的转移性NSCLC中总体安全。
  • 13例可评估患者中3例确认缓解,11例肿瘤负荷下降,中位最佳变化35%。
  • 治疗后检测到识别多种癌症突变的T细胞,且在缓解患者中富集。

核心结论

  • 自体TILs细胞治疗总体安全并具有临床活性,可能成为转移性肺癌的新治疗策略。

研究设计与样本

  • 单臂开放标签1期试验(NCT03215810),纳入20例纳武利尤单抗单药治疗后进展的晚期非小细胞肺癌患者。
  • 自体TILs由切碎肿瘤经白细胞介素-2培养体外扩增,患者接受环磷酰胺和氟达拉滨清淋、TIL输注及白细胞介素-2,随后纳武利尤单抗维持治疗。
  • 主要终点为安全性,次要终点包括客观缓解率、缓解持续时间和T细胞持久性。

主要发现

  • 安全性终点按预设的严重毒性≤17%标准达成(95%CI 3-29%)。
  • 13例可评估患者中3例确认缓解,11例肿瘤负荷下降,中位最佳变化35%。
  • 2例患者达到完全缓解,1.5年后仍持续。
  • 探索性分析显示治疗后检测到识别多种癌症突变的T细胞,且在缓解患者中富集。
  • 新抗原反应性T细胞克隆在外周血中增加并在治疗后持续存在。

临床怎么用

  • 在纳武利尤单抗单药治疗后进展的转移性NSCLC患者中,TILs联合纳武利尤单抗可作为1期试验背景下的候选治疗策略。

局限性

  • 单臂开放标签1期试验,样本量20例,可评估患者13例,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. We conducted a single-arm open-label phase 1 trial ( NCT03215810 ) of TILs administered with nivolumab in 20 patients with advanced non-small cell lung cancer following initial progression on nivolumab monotherapy. The primary end point was safety and secondary end points included objective response rate, duration of response and T cell persistence. Autologous TILs were expanded ex vivo from minced tumors cultured with interleukin-2. Patients received cyclophosphamide and fludarabine lymphodepletion, TIL infusion and interleukin-2, followed by maintenance nivolumab. The end point of safety was met according to the prespecified criteria of ≤17% rate of severe toxicity (95% confidence interval, 3-29%). Of 13 evaluable patients, 3 had confirmed responses and 11 had reduction in tumor burden, with a median best change of 35%. Two patients achieved complete responses that were ongoing 1.5 years later. In exploratory analyses, we found T cells recognizing multiple types of cancer mutations were detected after TIL treatment and were enriched in responding patients. Neoantigen-reactive T cell clonotypes increased and persisted in peripheral blood after treatment. Cell therapy with autologous TILs is generally safe and clinically active and may constitute a new treatment strategy in metastatic lung cancer.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Creelan BC, Wang C, Teer JK, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021. PMID: 34385708. doi:10.1038/s41591-021-01462-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。